Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03654560 · ClinicalTrials.gov registry record · NA
Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting
A NA study of Bleeding and Hemostasis, sponsored by United Health Products.
- Completed
- Registry status
- NA
- Development phase
- 236
- Enrollment target
- 1
- Study location
NCT03654560 is a NA study of Bleeding and Hemostasis that has completed, run by United Health Products. The registered enrollment target is 236 participants, below the 1,475-participant average among 23 other Bleeding trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03654560, a NA study of Bleeding and Hemostasis, has completed, sponsored by United Health Products.
- COMPLETED
- Registry status
- NA
- Development phase
- 236 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to assess efficacy and safety of HemoStyp as an adjunct for management of secondary hemostasis in the operative setting.
Conditions Studied
Interventions
- DEVICE HemoStyp
- DEVICE Surgicel
Study Locations (1)
California
- Raymond Schaerf - Burbank
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2018-12-28 |
| Est. Completion | 2019-09-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03654560
The ClinicalTrials.gov registry entry for NCT03654560 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 236 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,475-participant average among 23 other Bleeding trials with a reported enrollment target (84% lower). The listed sponsor is United Health Products, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bleeding appearing as the primary indexed condition, and to 2 interventions - of which HemoStyp is the first listed.
NCT03654560 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03654560 about?
NCT03654560 is a clinical study titled "Efficacy and Safety of HemoStyp as an Adjunct for Management of Secondary Hemostasis in the Operative Setting". The purpose of the study is to assess efficacy and safety of HemoStyp as an adjunct for management of secondary hemostasis in the operative setting.
What is the current status of trial NCT03654560?
This trial is currently completed. It is a NA study. The enrollment target is 236 participants. The study started on 2018-12-28. Estimated completion is 2019-09-12.
What conditions does trial NCT03654560 study?
This clinical trial studies the following conditions: Bleeding, Hemostasis.
What interventions are being tested in trial NCT03654560?
The interventions under investigation include: HemoStyp (DEVICE), Surgicel (DEVICE).
Who is sponsoring clinical trial NCT03654560?
This trial is sponsored by United Health Products, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03654560 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bleeding
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Quantra Point-of-Care Hemostasis Monitoring
RECRUITING · NA
-
SIMPLAAFY Clinical Trial
ACTIVE NOT RECRUITING · NA
-
Amplatzer Amulet LAAO vs. NOAC
ACTIVE NOT RECRUITING · NA
-
CHAMPION-AF Clinical Trial
ACTIVE NOT RECRUITING · NA
-
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
COMPLETED · NA
-
LEAVE Safe With DOACs
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.